Adverse events appear to unblind clinical trials in irritable bowel syndrome

Neurogastroenterology and Motility

Volumn 26, Issue 4, 2014, Pages 482-488

  Shah, E ^a   Triantafyllou, K ^a,b   Hana, A A ^a   Pimentel, M ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Clinical trials as topic; Double blind method; Drug toxicity; Endpoint determination; Irritable bowel syndrome

Indexed keywords

ALOSETRON; LINACLOTIDE; LUBIPROSTONE; PLACEBO; RIFAXIMIN; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADVERSE DRUG REACTION; ANOREXIA; ARM; ARTICLE; ATTRIBUTABLE RISK; CALCULATION; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DRUG EFFICACY; FLATULENCE; FLUSHING; HUMAN; IRRITABLE COLON; MEDICAL LITERATURE; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; CONTROLLED CLINICAL TRIAL (TOPIC); DOUBLE BLIND PROCEDURE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IRRITABLE BOWEL SYNDROME; PLACEBO EFFECT;

CONTROLLED CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IRRITABLE BOWEL SYNDROME; PLACEBO EFFECT;

EID: 84896393302     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12289     Document Type: Article

References (45)

1. Brandt LJ, Chey WD, Foxx-Orenstein AE et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104(Suppl. 1): S1-35.
2. Mangel AW, Hahn BA, Heath AT et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998; 26: 76-81.
3. Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010; 32: 144-58.
4. Viera AJ, Bangdiwala SI. Eliminating bias in randomized controlled trials: importance of allocation concealment and masking. Fam Med 2007; 39: 132-7.
5. Glasser SP, Howard G. Clinical trial design issues: at least 10 things you should look for in clinical trials. J Clin Pharmacol 2006; 46: 1106-15.
6. Beeh KM, Beier J, Donohue JF. Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res 2012; 13: 52.
7. Savović J, Jones H, Altman D et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess 2012; 16: 1-82.
8. Chey WD, Lembo AJ, Lavins BJ et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702-12.
9. Rao S, Lembo AJ, Shiff SJ et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-24; quiz p. 1725.
10. Shah E, Kim S, Chong K, Lembo A, Pimentel M. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med 2012; 125: 381-93.
11. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 1831-43; quiz 1844.
12. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
13. Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1084-92.
14. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145: 557-63.
15. Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
16. Lembo A, Zakko S, Ferreira N et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology 2008; 134: P-255.
17. Bardhan KD, Bodemar G, Geldof H et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 23-34.
18. Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149-59.
19. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-40.
20. Camilleri M, Chey WY, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-40.
21. Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005; 100: 115-23.
22. Krause R, Ameen V, Gordon SH et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol 2007; 102: 1709-19.
23. Chey WD, Chey WY, Heath AT et al. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2004; 99: 2195-203.
24. Lembo T, Wright RA, Bagby B et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2662-70.
25. Drossman DA, Toner BB, Whitehead WE et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19-31.
26. Vahedi H, Merat S, Momtahen S et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008; 27: 678-84.
27. Boerner D, Eberhardt R, Metz K, Schick E. Wirksamkeit und Verträglichkeit eines Antidepressivums beim Colon irritabile. Therapiewoche 1988; 38: 201-8.
28. Vij J, Jiloha R, Kumar N, Madhu S, Malika V, Anand B. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Indian J Psychiat 1991; 33: 243-6.
29. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 27: 685-96.
30. Drossman DA, Chey WD, Johanson JF et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-41.
31. Tack J, Müller-Lissner S, Bytzer P et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005; 54: 1707-13.
32. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
33. Kellow J, Lee OY, Chang FY et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-6.
34. Nyhlin H, Bang C, Elsborg L et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004; 39: 119-26.
35. Chey WD, Paré P, Viegas A, Ligozio G, Shetzline MA. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 2008; 103: 1217-25.
36. Zelmac (tegaserod) Advisory Committee Briefing Document. Novartis Pharmaceuticals Corporation. Avialble at: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b1a.pdf
37. Johnston JM, Kurtz CB, Macdougall JE et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010; 139: 1877-86, e1872.
38. Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 2013; 25: 453-7.
39. Andresen V, Hollerbach S. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Drug Saf 2004; 27: 283-92.
40. Wechsler ME, Kelley JM, Boyd IO et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 2011; 365: 119-26.
41. Lackner J, Jaccard J, Baum C et al. Patient-reported outcomes for irritable bowel syndrome are associated with patients' severity ratings of gastrointestinal symptoms and psychological factors. Clin Gastroenterol Hepatol 2011; 9: 957-64, e951.
42. Pimentel M, Talley NJ, Quigley EM, Hani A, Sharara A, Mahachai V. Report from the multinational irritable bowel syndrome initiative 2012. Gastroenterology 2013; 144: e1-5.
43. Kotsis V, Benson S, Bingel U et al. Perceived treatment group affects behavioral and neural responses to visceral pain in a deceptive placebo study. Neurogastroenterol Motil 2012; 24: 935-e462.
44. Wood L, Egger M, Gluud LL et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008; 336: 601-5.
45. Kaptchuk TJ, Friedlander E, Kelley JM et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE 2010; 5: e15591.